

May 08, 2024

To,

Listing Department

National Stock Exchange Of India Limited,

Exchange Plaza,

Bandra Kurla Complex,

Bandra (East), Mumbai- 400 051

NSE Symbol. VIJAYA

Dear Sir/Madam,

Sub: Investor Presentation

To,

The Corporate Relations Department

BSE Limited,

Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street,

Mumbai - 400 001

BSE Scrip Code. 543350

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation for Q4 & FY 2024 results and which would be used in the Investors / Analysts earnings conference call scheduled to be held on **May 09, 2024 at 11:00 a.m. IST.**

Please take the information on record.

Thanking you,

For Vijaya Diagnostic Centre Limited

Hansraj Singh Company Secretary & Compliance Officer M. No. F11438

Encl.: As Above





Q4 & FY24 Earnings Presentation, May 08 2024

Safe Harbour





This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Vijaya Diagnostic Centre Limited (the 'Company')**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Disclaimer





Note 1:

"With effect from 01 January 2023, the Company has changed its method of depreciation on all Property, Plant and Equipment from Written Down Value ("WDV") method to Straight Line Method ("SLM"), based upon the technical assessment of expected pattern of consumption of the future economic benefits embodied in the assets.

Due to the aforesaid change:

- o The depreciation expense is lower by Rs. 388.7 Mn for the full year ended March 31, 2024.
- \circ The Profit after tax (PAT) is higher by Rs. 290.8 Mn for the full year ended March 31, 2024.

Note 2:

Acquisition (PH Diagnostic Centre Private Limited, Pune): PH has become a whole owned subsidiary effective from 21st December, 2023. Consequently, its financials have been consolidated from 21st December, 2023 to 31st March, 2024. Hence, the revenue from operations for the period Q4 FY 24 and full year ended March 31, 2024 includes INR 117.7 Mn and Rs 130.6 Mn of PH respectively.



Q4 FY24 – Performance Snapshot (Y-o-Y & Q-o-Q)



	Q4 FY24	Q4 FY23	YoY %	Q3 FY24	QoQ %
Revenue ^	1,552	1,210	28.3%	1,327	17.0%
Revenue Excl. PH	1,434	1,210	18.5%	1,314	9.2%
EBIDTA	631	491	28.5%	523	20.7%
EBIDTA Margin	40.7%	40.6%	10 BPs	39.4%	130 BPs
Total tests	3.36	2.71	24.1%	2.88	16.7%
Total Footfall	0.98	0.80	21.4%	0.88	11.5%
(INR, millions) ^ Refer Slide no. 3 (Note 2)					

⁻ Q4 FY24 and Q3 FY24 numbers are including PH Pune, unless otherwise specified

⁻ PH has become a whole owned subsidiary effective from 21st December, 2023. Consequently, its financials have been consolidated from 21st December, 2023 to 31st March, 2024.





Operational & Financial Highlights – Q4 FY24



3.36 Mn Tests

0.98 Mn Footfalls



INR 1,552.1 Mn

Revenue from operations



Revenue

growth (YoY)

+18.5%

1

+14.7%

+17.1%

Test Volume growth (YoY)

Footfall growth (YoY)

Excluding PH



145 Centres

(Includes 18 centres of PH)



93% B2C Revenue



INR 631.1 Mn EBIDTA

40.7% EBIDTA Margin



INR 1,434.3 Mn

Revenue from

Operations

INR 334.5 Mn
Profit After Tax¹

21.6% PAT Margin

Note 1: Refer Slide no. 3

FY24 – Performance Snapshot





Operational & Financial Highlights – FY24



11.89 Mn Tests

3.55 Mn **Footfalls**



INR 5,478.1 Mn

Revenue from operations



Revenue

growth (YoY)

+16.4%

Excluding PH

Test Volume

growth (YoY)

+16.2% +9.9%

> Footfall growth (YoY)

145 Centres

(Includes 18 centres of PH)



94% **B2C** Revenue



INR 2,209.0 Mn **EBIDTA**

40.3% **EBIDTA Margin**



INR 5,347.5 Mn

Revenue from

Operations

INR 1,188.3 Mn

Profit After Tax¹

21.7% **PAT Margin**

INR 1,203.6 Mn

Normalized Profit After Tax²

22.0%

Normalized PAT Margin²

Note 1: Refer Slide no. 3

Note 2: Excluding one time M&A expenses of INR 20.5 Mn

Management comment







Commenting on the Q4FY24 results performance, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:

"I'm happy to share that this quarter too maintained our strong business performance, showcasing exceptional year-over-year revenue growth of 28.3%, of which an impressive 18.5% was achieved organically. This quarter also marked a notable milestone with the wellness contributing 14% of the revenue.

After completing six months of productive business operations, our Tier II hub centre in Mahbubnagar has gained a lot of momentum and broken even in just two quarters, showing a high demand for quality diagnostics in the area, and enforcing Vijaya's reputation as a trusted brand.


We have made significant strides toward integrating PH Pune with the parent firm. With effect from April 1st, 2024, we have successfully moved all of PH's essential ERP and other IT systems to the parent company's applications. Furthermore, it gives me great pleasure to announce that we have co-branded PH as Vijaya PH.


By strategically expanding and directing our capabilities towards future opportunities, we are confident in our ability to consistently deliver lasting value to our stakeholders."




























B2C Contribution – Q4 & FY24








Geographical Contribution - Revenue







Centre count as on 31.03.2024					
Hyderabad	RoAPT	Pune	Kolkata	Others	Total
92	31	18	2	2	145


Key Operational Highlights



















Consolidated Profit & Loss Account – Q4 & FY24



Particulars	Q4 FY24	Q4 FY23	Y-o-Y	Q3 FY24	Q-o-Q	FY24	FY23	Y-o-Y
Revenue from operations	1,552.1	1,209.9	28.3%	1,326.9	17.0%	5,478.1	4,592.2	19.3%
Cost of materials consumed	188.1	155.3	21.1%	159.9	17.7%	654.4	588.8	11.1%
Employee benefits expense	245.2	195.3	25.6%	230.3	6.5%	902.2	784.8	15.0%
Other expenses	487.6	368.3	32.4%	413.7	17.9%	1,712.5	1,398.4	22.5%
EBITDA	631.1	491.1	28.5%	523.1	20.7%	2,209.0	1,820.3	21.4%
EBITDA Margin (%)	40.7%	40.6%	10 BPs	39.4%	130 BPs	40.3%	39.6%	70 BPs
Other income	32.5	45.2	-28.1%	51.1	-36.4%	208.2	141.5	47.1%
Depreciation and amortization expense	163.0	113.6	43.5%	145.4	12.1%	570.0	617.2	-7.7%
EBIT	500.5	422.7	18.4%	428.7	16.7%	1,847.1	1,344.6	37.4%
Finance costs	61.9	57.7	7.4%	60.6	2.2%	239.9	209.5	14.5%
Profit before exceptional items and tax	438.7	365.0	20.2%	368.1	19.2%	1,607.3	1,135.1	41.6%
Exceptional items				20.5		20.5		
Profit before Tax	438.7	365.0	20.2%	347.6	26.2%	1,586.8	1,135.1	39.8%
Tax expenses	101.9	87.7	16.1%	87.6	16.3%	390.4	283.0	37.9%
Profit before Minority Interest	336.8	277.3	21.5%	260.0	29.5%	1,196.4	852.1	40.4%
Minority Interest	2.3	2.3	-3.1%	1.5	48.7%	8.1	5.8	41.1%
Profit after Tax (PAT)	334.5	274.9	21.7%	258.5	29.4%	1,188.3	846.3	40.4%
PAT Margin (%)	21.6%	22.7%	-110 BPs	19.5%	210 BPs	21.7%	18.4%	330 BPs
EPS – Basic (INR)*	3.3	2.7	21.4%	2.5	29.2%	11.6	8.3	40.2%

Note: Refer Slide no. 3

FY24 – Expanding Horizons







Inaugurated a state-of-the-art hub in Kolkata in July'23. This is the company's first center in Kolkata under the 'Vijaya' brand name. This 10,000 sq.ft facility has an automated lab and houses advanced radiology equipment like 3T MRI & 128 slice cardiac CT.



Penetrating Tier II Territory in Telangana – This Standalone Hub Centre in Mahbubnagar was inaugurated in Oct'23. This Centre is fully equipped to perform the whole gamut of diagnostics services from a routine blood test to advanced radiology modalities, right upto MRI.



'Comprehensive diagnostic services under one roof' model sets us apart in the region.




Enhancing customer experience





A comprehensive revamp of our main hub at Vishakhapatnam, after a decade long track record of stellar business performance. A significant upgrade to this advanced hub was the introduction of a futuristic PET CT machine, Vijaya's very first in Vishakhapatnam.



"Introduced an Open MRI at Ameerpet for a more comfortable MRI experience by addressing the aspect of greater comfort and the specific issue of claustrophobia, especially for children and elders."



About this company







Established in 2001, PH is Pune's largest B2C focused Integrated Diagnostic Chain. Being in the space for 23 long years, it has emerged as a brand of choice, enjoying the trust and patronage of customers across the region.

The founder, Dr. Hemanth Dhoka, a Doctor by profession and his family closely guard their vision of delivering quality healthcare and a convenient customer-experience by providing comprehensive diagnostic services under one roof.





Key Highlights



Type of Facility	Services Available	Count
Hubs	Sample collection, Ultrasound, X-Ray, 2D Echo, BMD, MRI, CT etc.,	3
Spokes	Sample collection, Ultrasound, X-Ray, 2D Echo etc.,	3
Collection Centres (Company run)	Sample collection only	12
Collection Centres (Franchisee)	Sample collection only	4
Total customer facing centres		22
Processing Laboratory		1

Type of Centres	Current annual	
	revenue rate per centre	
Hubs	~ INR 110 Mn +	
Spokes	~ INR 25 Mn +	
Collection & Franchisee Centres	~ INR 2 Mn +	

Particulars	FY 24
Revenue	INR 444.0 Mn
EBITDA	Inline with Vijaya's margin



High Quality Infrastructure













Superior Facilities













State-of-the-art Medical Equipment















Building a Stronger Future: Introducing Vijaya PH Diagnostic Centre











Building a Stronger Future: Introducing Vijaya PH Diagnostic Centre











Celebrating + YEARS Of trust

Expanding Strategically in alignment with our vision

Gurugram



Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain, expanding our reach.
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values.
- Consolidating our presence in Pune with a denser network, we plan to tap into potential markets in Western India.

East India Strategy

- With growing demand for quality diagnostic services, we are poised to confidently broaden our footprint in East India.
- Inaugured our second hub and first under the brand Vijaya in North Kolkata, marking a pivotal milestone in our network expansion strategy for the East.
- Employing our proven hub-and-spoke model, we aim to replicate our success in East India.

Pune

Adjacent Geography Strategy

•As a part our adjacent geographic expansion strategy, we opened a futuristic hub at Kalaburagi, marking our ever entry into state of Karnataka.

Core Market Strategy

•Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed.

Kolkata

- Ventured into Tirupati & Rajahmundry, and achieved break-even in less than two quarters. Inaugurated a hub in Mahbubnagar and expecting it to breakeven with in the anticipated timelines.
- A mammoth hub at Panjagutta, Hyderabad & new facility at Vizag witnessed overwhelming response.
- Broadening our geographic reach is expected to grow our customer base, effectively leveraging our established infrastructure.

The Pioneers in Diagnostic Medicare..



Vijaya at a Glance





Vijaya Diagnostic Centre Limited is the largest integrated diagnostic chain in South India with 145 state-of-the-art centres spread across 23 cities



Mission

Our Mission is to make the patient's medical journey faster, more transparent and more accurate. We are committed to deliver exceptional diagnostic solutions to every patient and physician



Vision

Our Vision is to provide reliable and accurate diagnostic services to our customers, at affordable prices, in a customer-centric manner. We strive to provide the best service possible. We are continually raising our own bar through the latest technology, continuous improvement and recruitment of high calibre technicians and professional



40+

Years of Experience

Experience in delivering Quality
Diagnostic Service
at affordable prices



145

Centres

State-of-the-art Facilities with Best-in-class Technology



Quality



23

Cities across India

Largest integrated player in South India



250+

Doctors

Radiologists, Pathologists & Microbiologists



Reliable & Accurate Diagnostics



~3.5 Mn

Footfalls

Trusted by every Age group



~11.9 Mn

Tests

Most preferred Diagnostic Centre




at Affordable Prices

Our Journey







1981

Recognized as one of the **Best Imaging centres in Hyderabad by The Week**

Awarded Brand of the year in diagnostic services by The **CEO Magazine and Telangana Healthcare** Leadership award

One of the earliest private diagnostic service providers to be approved for COVID RT-PCR testing by ICMR*

Awarded one of the Best **Healthcare Brands 2022 by The Economic Times**

Won the Healthcare Leadership Awards 2022

Awarded Pride of India Brands Award - The Best of South Awards

Acquired 100% stake in P.H. **Diagnostics and** forayed into Pune.

2023





2018

2020

2022



First independent diagnostic centre in South India to offer PET **CT from Wipro GE** Healthcare Pvt. Ltd.



Investment by **Karakoram Limited and Kedaara Capital Alternative Investment** Fund - Kedaara Capital AIF1



Awarded Best Diagnostic Centre – India by Times Healthcare Achievers Group



Successfully listed on Indian **Stock Exchanges (NSE & BSE)**

First independent diagnostic centre in Telangana to get **Revolution ACT 50 slice CT** from Wipro GE Healthcare Pvt. Ltd




Successfully launched the first center in Kolkata under the "Vijaya" brand name

*ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

At the Forefront of Introducing New Technologies





The Pioneers in Diagnostic Medicare..











...offering One-Stop Solutions for Pathology & Radiology



Complete Range of Diagnostic Services under One Roof

Comprehensive and high quality integrated diagnostic services through our operational network











Robust Technical Capabilities with State-of-the-art IT Infrastructure





30



8

CT Machines

PET CT / Gamma machines



29



250+

MRI Machines

Radiologists, Lab Doctors & **Physicians**



9

17

NABH Accreditations

NABL Accreditations



HOLOGIC®





BIOMÉRIEUX









BECKMAN


Key Suppliers





- Long standing relationship with medical technology vendors
- · At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Advanced Software to Manage Clinical Data





Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Front end IT infrastructure enabling...



Standardization across our operations



Closely track key performance metrics and maintain the Turn-**Around Time (TAT)**



Reduce incidence errors **Human Intervention**



Monitor Technical **Operations**



Provide Uniform Experience to from booking customers appointments accessing reports online







Vijaya Diagnostic Centre has been recognized as "Most trusted brand of India" by Marksmen Daily at 4th edition of the Most Trusted Brands of India.



Vijaya Diagnostic Centre has been recognized with "Most trusted brand of the Year Award" towards the 22nd Global Edition & 7th India Edition of Business Leader of the Year.



Dr. Hemant Dhoka, CEO of Vijaya PH Diagnostic Centre Pune, has been recognized as one of the Most Promising Business Leaders of Asia 2024 by ET Edge – Times Group









Vijaya Diagnostic Centre has been recognized for service excellence in integrated diagnostic care by the Time Group at the Times Health Excellence awards – Telangana 2023.



Vijaya Diagnostic Centre was awarded for excellence in comprehensive diagnostic care at the TV9 Bangla Suswasto Health Conclave and Excellence Awards held on August 18, 2023, at Swabhumi, Kolkata



Our consultant radiologist, Dr. Varsha Joshi, has made significant contributions as an Associate Editor to the recently published 8th Edition of David Sutton's Textbook of Radiology and Imaging. She has also authored two chapters on head and neck radiology within this book. Sutton's textbook stands as a well-established standard reference for both academic and clinical practices in the field of radiology.









Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Laboratory and Radiology in Hyderabad



Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Radiology



Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Laboratory and Radiology in Mahabubnagar









Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Laboratory in Nellore



Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Radiology in Hyderabad



Vijaya Diagnostic Centre has organized a continuing medical education (CME) on Radiology in Gulbarga



Experienced Board of Directors





Dr. S Surendranath Reddy – Founder and Executive Chairman

- Founder of Vijaya with 40+ years of experience in building Vijaya as South India's largest integrated diagnostic chain
- Holds Bachelor's degree in Medicine and Doctor of Medicine in Radiology



Dr. D Nageshwar Reddy - Non-executive, Independent Director

- Chairman of Asian Institute of Gastroenterology (AIG), Hyderabad
- Awarded Padma Shri and Padma Bhushan by Government of India
- D.M in Gastroenterology from PGIMER Chandigarh



Ms. Suprita Reddy - Managing Director and Chief Executive Officer

- With Vijaya since 2003 and heads overall strategy, clinical excellence, operations and expansion of the company
- Awarded Women Leadership Award in Healthcare by ABP
- Holds bachelors degree in commerce from Osmania University



Shekhar Prasad Singh - Non-executive, Independent Director

- Ex-Chief Secretary to Government of Telangana
- Retired IAS officer of 1983 batch



Sunil Chandra Kondapally - Executive Director

- Been with Vijaya since 2002 and 17+ years of experience in healthcare
- Holds Bachelor's degree in Electrical Engineering from Florida State University



Satyanaryana Murthy Chavali - Non-executive, Independent Director

- Ex-CEO of Aurigene Discovery Technologies Ltd.
- Holds BTech from IIT, Madras and MBA from IIM, Bangalore



S Geeta Reddy - Non-Executive Director

- Enrolled as advocate with Andhra Pradesh High Court in 1986
- Holds a Bachelor's degree in Law from Osmania University



Dr. Manjula Anagani - Non-executive, Independent Director

- Clinical Director and Head of Department of centre of women and childcare at Care hospitals
- Awarded Padma Shri by Government of India
- MD in Obstetrics and Gynecology from N.T.R. University of Health Sciences

Strong Management Team









Dr. S. Surendranath Reddy

Founder and Executive Chairman



Ms. Suprita Reddy

Managing Director and Chief Executive Officer



Mr. Sunil Chandra Kondapally

Executive Director



Mr. Narasimha Raju K.A

Chief Financial Officer



Mr. Sheshadri Vasan

Chief Operating Officer



Mr. Sivaramaraju Vegesna

Head – Strategy and Investor Relations



Mr. Hansraj Singh Rajput

Company Secretary & Compliance Officer

Awards & Accolades





Most Trusted Brand of India



2024 - 25 Brought to you Marksmen Daily at 4th edition

Most Trusted Brand of the Year



Presented by 22nd Global Edition & 7thl ndia Edition of Busi ness Leader of the Year.

Excellence In Comprehensive Diagnostic Care



Times Health Excellence Awards 2023

Excellence In Comprehensive Diagnostic Care



2023 ABP Ananda Swasthya Samman

Best Healthcare Brands



2023The Economic Times

Excellence In Comprehensive Diagnostic Care



2023ABP Ananda
Swasthya
Samman

As one of the 'Most Preferred Workplace 2022'



2022 - 23 Brought to you by Team Marksmen

Most Trusted Brand of the Year 2023



2023 Presented by Marksmen Daily

Best Healthcare Brands 2022



2022Presented by
The Economic
Times

Pride of India Brands Award 2022



2022 Presented by The Best of South Awards

One of the Best Healthcare Brands 2021



2021Presented by
The Economic
Times

Indo Global Award for Healthcare Excellence



Presented by Indian Economic Development & Research Association

Company of the Year -Healthcare



2021 Presented by TV9 Network and SAP

Leading Diagnostic Chain of the Year



2021
Presented by
Diagnostic
Leadership Summit

India's Greatest Brands 2020-21 Pride of Nation



2021
Presented by
United Research
Services

Leading Diagnostics with Excellence in Quality & Safety



2021
Presented by
Diagnostic
Leadership
Summit

Most Trusted and Best Quality Diagnostic services in India



2020
Presented by
Times
Healthcare
Achievers

Healthcare Entrepreneur of the Year – Dr. Surendra Reddy




2019
Presented by
Six Sigma
Healthcare



Shareholding Pattern as of 31st March 2024





DII's: Mutual Funds, AIF's and QIB's Others: Retail, Bodies Corporate and others




Robust Operational Metrics







Diagnostic Centre (Nos)




Footfalls (Mn)









Test per Footfall (Nos)



Revenue per Test (INR)




Revenue per Footfall (INR)





Consistent Financial Performance























Sustainable Cash Generation & Increasing Return Ratios
















Consolidated Profit & Loss Account



Particulars	FY24	FY23	FY22	FY21	FY20
Revenue from operations	5,478	4,592	4,624	3,767	3,388
Cost of materials consumed	654	589	715	571	439
Employee benefits expense	902	785	707	574	624
Other expenses	1,712	1,398	1,165	962	999
EBITDA	2,209	1,820	2,037	1,660	1,326
EBITDA %	40.3%	39.6%	44.1%	44.1%	39.1%
Other income	208	142	128	118	154
Depreciation and amortization expense	570	617	527	505	492
EBIT	1,847	1,344	1,638	1,274	988
Finance costs	240	209	165	152	154
Profit before tax and exceptional items	1,607	1,135	1,474	1,121	834
Exceptional items	21	_	-	_	-
Profit before Tax	1,587	1,135	1,474	1,121	834
Tax expenses	390	283	367	270	209
Profit after Tax before Minority Interest	1,196	852	1,107	851	625
Minority Interest	8	5.8	10	6	0
Profit after Tax	1,188	846	1,097	845	625
PAT %	21.7%	18.4%	23.7%	22.4%	18.5%
EPS – Basic (INR)	11.62	8.29	10.76	8.28	6.13

Note: Refer Slide no. 3

Consolidated Balance Sheet







Assets	Mar-24	iviar-23	Mar-22	iviar-21	Mar-20
NON-CURRENT ASSETS	7,714	5,777	4,436	3,022	2,959
Property, plant and equipment	3,785		-		-
Capital work-in-progress	83	271	341	82	93
Goodwill	1,192	53	53	53	53
Other intangible assets	207	22	14	6	10
Right of use asset	2,235	2,223	1,672	1,260	1,254
Intangible assets under development	5	6	1	12	4
Financial assets					
- Investments	0	0	0	0	0
- Other financial assets	113	90	75	122	55
Deferred tax assets	29	83	89	61	16
Income tax assets	2	2	2	6	9
Other assets	62	85	223	61	67
CURRENT ASSETS	2,113	2,757	2,698	2,388	1,865
Inventories	52			26	
Financial assets					
- Investments	1,091	1,390	542	276	547
- Trade receivables	162	95	98	64	80
- Cash and cash equivalents	222	242	110	67	556
- Bank balances other than Cash and cash equivalents	508	922	1,813	1,876	626
- Loans	0	0	0	0	1
- Other financial assets	31	36	51	52	5
Other current assets	46	51	41	27	22
TOTAL ASSETS	9,828	8,534	7,135	5,409	4,824

EQUITY AND LIABILITIES	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20
EQUITY	6,599	5,466	4,695	3,592	2,741
Equity share capital	102	102	102	45	45
Instruments entirely equity in nature	-	-	-	-	-
Other equity	6,497	5,364	4,593	3,547	2,696
NON-CURRENT LIABILITIES	2,500	2,406	1,778	1,377	1,494
Financial liabilities					
- Borrowings	0	0	0	33	221
- Lease liabilities	2,391	2,330	1,703	1,265	1,196
- Other financial liabilities	0	0	0	2	9
Provisions	106	71	74	77	67
Other liabilities	3	5	1	1	1
CURRENT LIABILITIES	729	662	661	440	589
Financial liabilities					
- Borrowings	0	0	6	12	13
- Lease liabilities	201	145	126	101	88
- Trade payables	329	277	216	222	217
- Other financial liabilities	114	140	248	61	224
Income tax liabilities	12	24	9	16	15
Provisions	32	40	21	7	11
Other liabilities	40	36	35	20	21
TOTAL EQUITY AND LIABILITIES	9,828	8,534	7,135	5,409	4,824







Particulars	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20
Cash Flow from Operating Activities					
Profit before Tax	1,587	1,135	1,474	1,121	834
Adjustment for Non-Operating Items	599	683	572	534	492
Operating Profit before Working Capital Changes	2,186	1,818	2,046	1,655	1,326
Changes in Working Capital	-14	90	-67	-46	-32
Cash Generated from Operations	2,172	1,908	1,979	1,609	1,294
Less: Direct Taxes paid	-339	-262	-399	-312	-233
Net Cash from Operating Activities	1,833	1,646	1,580	1,297	1,061
Purchase and construction of property, plant and building (net)	-880	-1,248	-1,223	-312	-375
Acquisition of subsidiary	-1,475	_	_	_	-
Investments (net)	530	734	-127	-1,033	11
Others	401	887	120	47	57
Cash Flow from Investing Activities	-1,423	-1,096	-1,231	-1,298	-306
Cash Flow from Financing Activities	-445	-419	-306	-488	-295
Net increase/ (decrease) in Cash & Cash equivalent	-36	131	44	-489	460
Cash & Cash Equivalents at the beginning of the period	258	110	67	556	96
Cash & Cash equivalents at the end of the period	222	242	110	67_	556

Cash and Cash Equivalents

Particulars	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20
Investments*	1,092	1,390	542	335	547
Cash and cash equivalents	222	242	110	67	556
Bank balances other than Cash and cash equivalents	508	922	1,813	1,876	626
Total	1,822	2,554	2,465	2,277	1,729



Thank You

For further information please contact:

Mr. Siva Rama Raju Head – Strategy & Investor Relations +91 99485 95555

sivaramaraju.v@vijayadiagnostic.in ir@vijayadiagnostic.in

www.vijayadiagnostic.com